Literature DB >> 28473037

Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening.

Lila J Finney Rutten1, Robert M Jacobson2, Patrick M Wilson3, Debra J Jacobson3, Chun Fan3, John B Kisiel4, Seth Sweetser4, Sidna M Tulledge-Scheitel5, Jennifer L St Sauver6.   

Abstract

OBJECTIVES: To characterize early adoption of a novel multitarget stool DNA (MT-sDNA) screening test for colorectal cancer (CRC) screening and to test the hypothesis that adoption differs by demographic characteristics and prior CRC screening behavior and proceeds predictably over time. PATIENTS AND METHODS: We used the Rochester Epidemiology Project research infrastructure to assess the use of the MT-sDNA screening test in adults aged 50 to 75 years living in Olmsted County, Minnesota, in 2014 and identified 27,147 individuals eligible or due for screening colonoscopy from November 1, 2014, through November 30, 2015. We used electronic Current Procedure Terminology and Health Care Common Procedure codes to evaluate early adoption of the MT-sDNA screening test in this population and to test whether early adoption varies by age, sex, race, and prior CRC screening behavior.
RESULTS: Overall, 2193 (8.1%) and 974 (3.6%) individuals were screened by colonoscopy and MT-sDNA, respectively. Age, sex, race, and prior CRC screening behavior were significantly and independently associated with MT-sDNA screening use compared with colonoscopy use after adjustment for all other variables (P<.05 for all). The rates of adoption of MT-sDNA screening increased over time and were highest in those aged 50 to 54 years, women, whites, and those who had a history of screening. The use of the MT-sDNA screening test varied predictably by insurance coverage. The rates of colonoscopy decreased over time, whereas overall CRC screening rates remained steady.
CONCLUSION: The results of the present study are generally consistent with predictions derived from prior research and the diffusion of innovation framework, pointing to increasing use of the new screening test over time and early adoption by younger patients, women, whites, and those with prior CRC screening.
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28473037      PMCID: PMC5505626          DOI: 10.1016/j.mayocp.2017.01.019

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  30 in total

1.  Healthcare system factors and colorectal cancer screening.

Authors:  Jane G Zapka; Elaine Puleo; Maureen Vickers-Lahti; Roger Luckmann
Journal:  Am J Prev Med       Date:  2002-07       Impact factor: 5.043

2.  Using diffusion of innovations and academic detailing to spread evidence-based practices.

Authors:  Clark Carboneau
Journal:  J Healthc Qual       Date:  2005 Mar-Apr       Impact factor: 1.095

3.  Lessons for guidelines from the diffusion of innovations.

Authors:  E M Rogers
Journal:  Jt Comm J Qual Improv       Date:  1995-07

4.  The patient record in epidemiology.

Authors:  L T Kurland; C A Molgaard
Journal:  Sci Am       Date:  1981-10       Impact factor: 2.142

5.  Colorectal cancer-screening tests and associated health behaviors.

Authors:  J A Shapiro; L C Seeff; M R Nadel
Journal:  Am J Prev Med       Date:  2001-08       Impact factor: 5.043

6.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

7.  Inequalities in adoption of cancer screening from a diffusion of innovation perspective: identification of late adopters.

Authors:  Myung-Il Hahm; Eun-Cheol Park; Kui Son Choi; Hoo-Yeon Lee; Jae-Hyun Park; Sohee Park
Journal:  Cancer Epidemiol       Date:  2010-10-13       Impact factor: 2.984

8.  Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force.

Authors:  Ann G Zauber; Iris Lansdorp-Vogelaar; Amy B Knudsen; Janneke Wilschut; Marjolein van Ballegooijen; Karen M Kuntz
Journal:  Ann Intern Med       Date:  2008-10-06       Impact factor: 25.391

9.  Multitarget stool DNA testing for colorectal-cancer screening.

Authors:  Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Theodore R Levin; Philip Lavin; Graham P Lidgard; David A Ahlquist; Barry M Berger
Journal:  N Engl J Med       Date:  2014-03-19       Impact factor: 91.245

10.  Individual- and provider-level factors associated with colorectal cancer screening in accordance with guideline recommendation: a community-level perspective across varying levels of risk.

Authors:  Ryan J Courtney; Christine L Paul; Robert W Sanson-Fisher; Finlay A Macrae; Mariko L Carey; John Attia; Mark McEvoy
Journal:  BMC Public Health       Date:  2013-03-20       Impact factor: 3.295

View more
  4 in total

1.  Performance of multitarget stool DNA testing in African American patients.

Authors:  Gregory S Cooper; Sanford D Markowitz; Zhengyi Chen; Missy Tuck; Joseph E Willis; Barry M Berger; Dean E Brenner; Li Li
Journal:  Cancer       Date:  2018-09-07       Impact factor: 6.860

2.  Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries.

Authors:  Steffie K Naber; Amy B Knudsen; Ann G Zauber; Carolyn M Rutter; Sara E Fischer; Chester J Pabiniak; Brittany Soto; Karen M Kuntz; Iris Lansdorp-Vogelaar
Journal:  PLoS One       Date:  2019-09-04       Impact factor: 3.240

Review 3.  DNA methylation detection methods used in colorectal cancer.

Authors:  Yu-Xia Zhan; Guang-Hua Luo
Journal:  World J Clin Cases       Date:  2019-10-06       Impact factor: 1.337

4.  Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy.

Authors:  Jason D Eckmann; Derek W Ebner; Jamie Bering; Allon Kahn; Eduardo Rodriguez; Mary E Devens; Kari L Lowrie; Karen Doering; Sara Then; Kelli N Burger; Douglas W Mahoney; David O Prichard; Michael B Wallace; Suryakanth R Gurudu; Lila J Finney; Paul Limburg; Barry Berger; David A Ahlquist; John B Kisiel
Journal:  Am J Gastroenterol       Date:  2020-04       Impact factor: 12.045

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.